118 related articles for article (PubMed ID: 22006014)
1. Prostate cancer in the elderly: frequency of advanced disease at presentation and disease-specific mortality.
Scosyrev E; Messing EM; Mohile S; Golijanin D; Wu G
Cancer; 2012 Jun; 118(12):3062-70. PubMed ID: 22006014
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen screening for prostate cancer and the risk of overt metastatic disease at presentation: analysis of trends over time.
Scosyrev E; Wu G; Mohile S; Messing EM
Cancer; 2012 Dec; 118(23):5768-76. PubMed ID: 22847578
[TBL] [Abstract][Full Text] [Related]
3. Progression of mean age and mean expected mortality rate by duration of follow up in cohorts with a wide range of age.
Singer RB
J Insur Med; 2006; 38(3):181-91. PubMed ID: 17076138
[TBL] [Abstract][Full Text] [Related]
4. [Epidemiologic indicators of adenocarcinoma of the prostate. Results on 436 patients].
Arrizabalaga Moreno M; García González JI; Diez Rodríguez JM; Esteban Artiaga R; Castro Pita M; Navarro Sebastian J; Mora Durbán M; Paniagua Andrés P
Actas Urol Esp; 1997 Oct; 21(9):852-61. PubMed ID: 9471868
[TBL] [Abstract][Full Text] [Related]
5. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
6. Competing risk analysis after radical prostatectomy for clinically nonmetastatic prostate adenocarcinoma according to clinical Gleason score and patient age.
Sweat SD; Bergstralh EJ; Slezak J; Blute ML; Zincke H
J Urol; 2002 Aug; 168(2):525-9. PubMed ID: 12131302
[TBL] [Abstract][Full Text] [Related]
7. The National Prostate Cancer Register in Sweden 1998-2002: trends in incidence, treatment and survival.
Varenhorst E; Garmo H; Holmberg L; Adolfsson J; Damber JE; Hellström M; Hugosson J; Lundgren R; Stattin P; Törnblom M; Johansson JE
Scand J Urol Nephrol; 2005; 39(2):117-23. PubMed ID: 16019764
[TBL] [Abstract][Full Text] [Related]
8. Prostate cancer-specific mortality after definitive radiation therapy: who dies of disease?
Kim MM; Hoffman KE; Levy LB; Frank SJ; Pugh TJ; Choi S; Nguyen QN; McGuire SE; Lee AK; Kuban DA
Eur J Cancer; 2012 Jul; 48(11):1664-71. PubMed ID: 22336663
[TBL] [Abstract][Full Text] [Related]
9. Age at diagnosis and age at death in familial prostate cancer.
Brandt A; Bermejo JL; Sundquist J; Hemminki K
Oncologist; 2009 Dec; 14(12):1209-17. PubMed ID: 19939895
[TBL] [Abstract][Full Text] [Related]
10. Prostate cancer death of men treated with initial active surveillance: clinical and biochemical characteristics.
Krakowsky Y; Loblaw A; Klotz L
J Urol; 2010 Jul; 184(1):131-5. PubMed ID: 20478589
[TBL] [Abstract][Full Text] [Related]
11. Impact of competing mortality on the cancer-related mortality in localized prostate cancer.
Aus G; Pileblad E; Hugosson J
Urology; 1995 Nov; 46(5):672-5. PubMed ID: 7495119
[TBL] [Abstract][Full Text] [Related]
12. The clinical burden of prostate cancer in Canada: forecasts from the Montreal Prostate Cancer Model.
Grover SA; Coupal L; Zowall H; Rajan R; Trachtenberg J; Elhilali M; Chetner M; Goldenberg L
CMAJ; 2000 Apr; 162(7):977-83. PubMed ID: 10763395
[TBL] [Abstract][Full Text] [Related]
13. Prostate cancer mortality in northern Sweden, with special reference to tumor grade and patient age.
Grönberg H; Damber L; Jonson H; Damber JE
Urology; 1997 Mar; 49(3):374-8. PubMed ID: 9123701
[TBL] [Abstract][Full Text] [Related]
14. Cause-specific mortality following radical prostatectomy.
Shikanov S; Kocherginsky M; Shalhav AL; Eggener SE
Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):106-10. PubMed ID: 22083265
[TBL] [Abstract][Full Text] [Related]
15. Trends in survival of patients diagnosed with male genital cancers in the Nordic countries 1964-2003 followed up until the end of 2006.
Bray F; Klint A; Gislum M; Hakulinen T; Engholm G; Tryggvadóttir L; Storm HH
Acta Oncol; 2010 Jun; 49(5):644-54. PubMed ID: 20151937
[TBL] [Abstract][Full Text] [Related]
16. Prostate cancer. Mortality and morbidity after non-curative treatment with aspects on diagnosis and treatment.
Aus G
Scand J Urol Nephrol Suppl; 1994; 167():1-41. PubMed ID: 7542397
[TBL] [Abstract][Full Text] [Related]
17. Incidence and pathological characteristics of prostate cancer in Italy: a contribution to the screening debate.
Picone GM; Pizzi C; Quartuccio A; Scognamiglio G; Tauchmanova L; Di Maio M; Cifarelli P; Contegiacomo A
Cancer Detect Prev; 2006; 30(5):455-8. PubMed ID: 17067751
[TBL] [Abstract][Full Text] [Related]
18. Survival benefit of radical prostatectomy in patients with localized prostate cancer: estimations of the number needed to treat according to tumor and patient characteristics.
Abdollah F; Sun M; Schmitges J; Thuret R; Bianchi M; Shariat SF; Briganti A; Jeldres C; Perrotte P; Montorsi F; Karakiewicz PI
J Urol; 2012 Jul; 188(1):73-83. PubMed ID: 22578732
[TBL] [Abstract][Full Text] [Related]
19. Cancer mortality at very old ages.
Smith DW
Cancer; 1996 Apr; 77(7):1367-72. PubMed ID: 8608517
[TBL] [Abstract][Full Text] [Related]
20. Trends in mortality rates in patients with prostate cancer during the era of prostate specific antigen screening.
Merrill RM; Stephenson RA
J Urol; 2000 Feb; 163(2):503-10. PubMed ID: 10647666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
